Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac safety of glycopyrrolate added to Foster in moderate to severe COPD
2011-004759-37Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium and beclometasone dipropionate + formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in average 24-hour heart rate at Visit 5. Started Dec 2011; status: completed.
02
Drugs
glycopyrroniumbeclometasone dipropionate + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-004759-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004759-37.